Mohit Bansal
Stock Analyst at Wells Fargo
(4.23)
# 348
Out of 4,829 analysts
163
Total ratings
60%
Success rate
10.38%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $65.87 | -1.32% | 7 | May 7, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $750 → $700 | $527.78 | +32.63% | 17 | Apr 30, 2025 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $0.71 | +41.00% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $734.57 | +49.75% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $96.91 | +44.46% | 11 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $240 | $184.60 | +30.01% | 8 | Mar 5, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $118.17 | +18.47% | 13 | Feb 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | $130 → $170 | $97.78 | +73.86% | 2 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $60 → $62 | $46.45 | +33.48% | 8 | Feb 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Equal-Weight | $460 | $424.99 | +8.24% | 10 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $265.86 | +5.32% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $23.96 | +25.21% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $92.87 | +83.06% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $21.71 | +222.43% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $125 → $110 | $75.97 | +44.79% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $20.02 | +34.87% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $58.86 | +52.91% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $22.28 | +34.65% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $115.71 | +46.92% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $14.60 | +84.93% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $35.02 | +42.78% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $6.29 | +29,709.22% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $29.34 | +2.25% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.95 | +3,697.87% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $12.02 | +58.07% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.29 | +1,608.82% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.44 | +4,066.67% | 4 | Dec 3, 2019 |
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $65.87
Upside: -1.32%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Overweight
Price Target: $750 → $700
Current: $527.78
Upside: +32.63%
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $0.71
Upside: +41.00%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $734.57
Upside: +49.75%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $96.91
Upside: +44.46%
AbbVie
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $184.60
Upside: +30.01%
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $118.17
Upside: +18.47%
Jazz Pharmaceuticals
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $97.78
Upside: +73.86%
Bristol-Myers Squibb Company
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $46.45
Upside: +33.48%
Vertex Pharmaceuticals
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $424.99
Upside: +8.24%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $265.86
Upside: +5.32%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $23.96
Upside: +25.21%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $92.87
Upside: +83.06%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $21.71
Upside: +222.43%
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $75.97
Upside: +44.79%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $20.02
Upside: +34.87%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $58.86
Upside: +52.91%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $22.28
Upside: +34.65%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $115.71
Upside: +46.92%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $14.60
Upside: +84.93%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $35.02
Upside: +42.78%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $6.29
Upside: +29,709.22%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $29.34
Upside: +2.25%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $0.95
Upside: +3,697.87%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $12.02
Upside: +58.07%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.29
Upside: +1,608.82%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.44
Upside: +4,066.67%